
Britain's best-selling car brands revealed with ‘devastatingly handsome' Ford STILL topping the charts
We're over halfway through the year, and Autocar has updated its list of the most popular car brands – with one model jumping up to break into the top five.
5
However, the Ford Puma has retained its top spot despite low sales at the beginning of the year.
Last month saw a 1.6 per cent rise in car sales, with a whopping 150,070 vehicles sold in May.
There's also been a 25.8 per cent surge in EV sales, adding 32,738 more electric cars to UK roads.
Despite the increase in electric motors, there were no Tesla models in the top 10 most bought cars.
Here are the most popular cars in 2025 so far.
Ford Puma - 21,936 units
The Ford Puma remains the best-selling car of the year, just as it was in 2024.
It had a slow start to the year, but after three straight months of strong sales, it's climbed back to the top spot.
The popular model appeals to drivers with its affordable pricing and range of options, including the sporty Puma ST variant.
The upcoming release of the electric Ford Puma Gen-E will help cement its top spot status.
Kia Sportage - 19,636 units
This SUV is 'fresh, eye-catching and modern,' as described by Autocar.
Its designers in Seoul will be thrilled to see the much-loved model hold onto second place for another month running.
The Kia Sportage offers mild-hybrid, full-hybrid, and plug-in hybrid options, giving buyers plenty of choice.
Built in Europe, the car has a futuristic design which car expert Matt Saunders said caught his imagination.
Matt said: 'Not sure if it was aircraft tail fins or T-bone steaks that those air vents reminded me of, but I certainly kept coming back to look at them.
'Sometimes character/full product design can be just that simple.'
Nissan Qashqai - 17,077 units
This Nissan was the most sought-after car in 2022, but has since been leapfrogged by its competitors.
Despite a recent dip, it remains a popular choice among drivers thanks to its strong practicality and ongoing appeal.
The SUV is so popular that the average Brit is said to always be within 500m of one.
The Nissan Qashqai's sales have been boosted by the addition of electrified powertrains in its third generation.
5
Vauxhall Corsa - 16,545 units
The Vauxhall Corsa has had a rollercoaster ride in annual car sales, hitting number one in 2021 before dropping out of the top 10 in 2024.
In response to weak sales, Vauxhall completely redesigned the model.
The Corsa now features a sleek, modern design and upgraded technology, giving it a more luxurious feel.
The overhaul was an apparent success, with the Corsa now taking the number four spot for the most bought car in the UK.
5
Nissan Juke – 15,249 units
The Nissan Juke is the newest model to climb the ranks, overtaking the Volkswagen Golf in Autocar's updated list of best-selling cars.
The small SUV continues to be popular, securing fourth place in 2024.
It got a facelift in mid-2023, which also introduced hybrid power for the first time.
The UK's most popular cars for this year have been revealed.
The Ford Puma has taken the first place spot for the second year in a row.
However, there has been a major shakeup across the Top 10 as Tesla sales plummet in the UK and Europe.
Here's the top 10 most bought cars in the UK:
1. Ford Puma – 21,936 units
2. Kia Sportage – 19,636 units
3. Nissan Qashqai – 17,077 units
4. Vauxhall Corsa – 16,545 units
5. Nissan Juke – 10,414 units
6. Volkswagen Golf – 10,749 units
7. MG HS - 9738 units
8. Volkswagen Tiguan - 9140 units
9. Volvo XC40 - 12,606 units
10. MG HS - 12,545 units

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


ITV News
7 minutes ago
- ITV News
UK-India trade deal sparks fears over access to cheap medicines for millions
A newly signed trade agreement between India and the UK has triggered concerns that millions of poor Indians may lose access to affordable life-saving medicines. Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs. 'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies. India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar. Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands. 'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University. 'Voluntary licences often come with strings attached and don't bring the same price reductions.' Weakening India's Patent Safeguards Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India. Instead, disclosures can be made every three years, and some information can be kept confidential. Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence. There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents. Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections. 'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group. 'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.' The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries. Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders. Government response The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade. Officials insist that India has preserved its ability to protect public health. But rights groups remain unconvinced. 'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad. 'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.' Broader implications The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards. Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies. But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance? From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...


The Independent
37 minutes ago
- The Independent
Trump claims ‘migrant invasion is killing Europe' during Scotland visit
Donald Trump arrived in Scotland for a four-day visit, intending to golf at his luxury resorts and engage with leaders. Upon landing at Glasgow Prestwick Airport, he was greeted by thousands and met by Scottish Secretary Ian Murray. Trump praised Prime Minister Keir Starmer as a "good man" and confirmed a meeting, commending him for securing a trade deal. He advised European leaders to "get your act together" on immigration, labelling it an "invasion" that is "killing Europe". Trump also criticised windmills, claiming they are "ruining your countries" and harming the environment.


The Independent
37 minutes ago
- The Independent
F1 live streams: Link to watch Belgian Grand Prix sprint race online
F1 returns after a three-week mid-season break for the Belgian Grand Prix at the famous Spa-Francorchamps circuit - and the third sprint weekend of the 2025 season. Lando Norris won his home race last time out at the British Grand Prix, capitalising on teammate Oscar Piastri 's penalty to claim his second victory in a row. Piastri's lead in the world championship is now just eight points at the halfway stage of the season. Nico Hulkenberg secured his first-ever podium in F1 at Silverstone, while Lewis Hamilton once again finished fourth as he continues to chase a first podium in Ferrari red. Hamilton won last year's race at Spa-Francorchamps after George Russell was disqualified. This weekend's race will also be the first since Christian Horner's dismissal at Red Bull, with Laurent Mekies taking charge for the first time. When is the Belgian Grand Prix? All times BST Saturday 26 July Sprint race: 11am Qualifying: 3pm Sunday 27 July Race: 2pm How can I watch it online and on TV? The Belgian Grand Prix will be broadcast live on Sky Sports in the United Kingdom - and ESPN in the United States. Sky's coverage of Sunday's race starts at 12:30pm (BST). Sky Sports subscribers can watch all the action at Spa-Francorchamps on the Sky Go app. If you're not a Sky customer, you can grab a NOWTV Day Pass here to watch without a subscription. If you're travelling abroad and want to watch the Belgian Grand Prix then you might need a VPN to unblock your streaming app. Our VPN roundup is here to help. F1 driver standings 1. Oscar Piastri (McLaren) – 234 points 2. Lando Norris (McLaren) – 226 points 3. Max Verstappen (Red Bull) – 165 points 4. George Russell (Mercedes) – 147 points 5. Charles Leclerc (Ferrari) – 119 points 6. Lewis Hamilton (Ferrari) – 103 points 7. Kimi Antonelli (Mercedes) – 63 points 8. Alex Albon (Williams) – 46 points 9. Nico Hulkenberg (Sauber) - 37 points 10. Esteban Ocon (Haas) – 23 points 12. Isack Hadjar (Racing Bulls) – 21 points 12. Lance Stroll (Aston Martin) – 20 points 13. Pierre Gasly (Alpine) – 19 points 14. Fernando Alonso (Aston Martin) – 16 points 15. Carlos Sainz (Williams) – 13 points 16. Liam Lawson (Racing Bulls) – 12 points 17. Yuki Tsunoda (Red Bull) – 10 points 18. Ollie Bearman (Haas) – 6 points 19. Gabriel Bortoleto (Sauber) – 4 points 20. Franco Colapinto (Alpine) – 0 points 21. Jack Doohan (Alpine) – 0 points F1 constructor standings 1. McLaren - 460 points 2. Ferrari - 222 points 3. Mercedes - 210 points 4. Red Bull - 172 points 5. Williams - 59 points 6. Sauber - 41 points 7. Racing Bulls - 36 points 8. Aston Martin - 36 points 9. Haas - 29 points 10. Alpine - 19 points 2025 F1 CALENDAR IN FULL: ROUND 13 - BELGIUM (sprint weekend) Circuit de Spa-Francorchamps - 25-27 July ROUND 14 - HUNGARY Hungaroring, Budapest - 1-3 August ROUND 15 - NETHERLANDS Circuit Zandvoort - 29-31 August ROUND 16 - ITALY Monza Circuit - 5-7 September ROUND 17 - AZERBAIJAN Baku City Circuit - 19-21 September ROUND 18 - SINGAPORE Marina Bay Street Circuit - 3-5 October ROUND 19 - UNITED STATES (sprint weekend) Circuit of the Americas, Austin - 17-19 October ROUND 20 - MEXICO Autodromo Hermanos Rodriguez, Mexico City - 24-26 October ROUND 21 - BRAZIL (sprint weekend) Interlagos Circuit, Sao Paulo - 7-9 November ROUND 22 - LAS VEGAS Las Vegas Street Circuit - 20-22 November ROUND 23 - QATAR (sprint weekend) Lusail International Circuit, Lusail - 28-30 November